ANTIVIRAL RESISTANT STRAIN
HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated. These mutations confer resistance to specific HIV protease inhibitors and have been reported for emerging virus in vivo.
Product Risk Group:
Group M virus
Viral Storage Medium -80C
Infectivity tested and quantified
>10e8 RNA copies (>10e6 infectious particles)
(Cost per access for Academics)
2 000,00 €
infectious material; strictly for handling within BSL-3 environment
infection of susceptible human cell lines (Hut78, 293T, CEM, SX22-1 as Hela-derivative)
Production cell line:
Friday, 1 January, 2010
site-specific mutagenesis in accordance with mutations found in sequences from patient-derived virus
Derived from emerging drug-resistant virus from patient with elevated viral load.